This report investigates review designations in the pharmaceutical industry from the standpoint of drug development. It provides an in- depth review of the history and available designations alongside high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern teh impact these designations have had on the market and on the drug products themselves.
Scope
This report gives important, expert insight you won’t find in any other source. 23 figures throughout the report illustrate major points, trends and impacts review designations have had upon the Pharmaceutical industry . This report is required reading for:- Investors that want to understand the impact key review designations like Orphan Drug Designations could have on companies.
- Professional Services that are interested in understanding the impact review designations have had on the Biopharmaceutical industry
- Large pharma companies interested in lifecycle management of their portfolio and want to see how they can extend or expand their portfolios’ reach
- Small and medium pharma who may want to secure review designations and want to see how it could impact their portfolio
Reasons to Buy
- Insights on how review designations impacted drug development
- Insights on how drug approvals may impact future drug development and approval trends
- Sales and regulatory-based insights into 2023 covering various drugs and companies
Table of Contents
1 Introduction to Review Designations1.1 Definitions
1.2 Timeline of key events
2 Review Designation Trends
2.1 Designations awarded by time
2.2 Designations by type
2.3 Designations by region
2.4 Top therapy areas
2.5 Top companies
3 Impact of Review Designations
3.1 Impact on approvals
3.2 Impact on sales
4 Key Findings
5 Appendix
5.1 Abbreviations
5.2 About the Authors
5.3 About the Analyst
5.4 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer
- Merck & Co,Novartis AG
- Johnson & Johnson
- Abbvie
- F.Hoffman-La Roche Ltd
- Bristol-Myers Squibb Co
- Astrazeneca Plc
- Takeda Pharmaceutical
- GlaxoSmithKline Plc
- GSK
- Amgen
- Novartia AG
- Sanofi
- Ono Pharmaceutical
- Beigene
- Yangtze River Pharmaceutical group
- Zai Lab
- Sino Biopharmaceutical
- Innovent Biologics
- Jiangsu Hengrul Medicine
